Berliner Boersenzeitung - Mixed results for Moderna mRNA flu vaccine trial

EUR -
AED 3.933575
AFN 73.194364
ALL 98.071859
AMD 416.755468
ANG 1.940964
AOA 977.239777
ARS 1071.6207
AUD 1.626849
AWG 1.927711
AZN 1.817334
BAM 1.953248
BBD 2.174459
BDT 128.691851
BGN 1.953521
BHD 0.40597
BIF 3179.645478
BMD 1.070951
BND 1.42344
BOB 7.458255
BRL 6.145006
BSD 1.076993
BTN 90.861281
BWP 14.283337
BYN 3.524395
BYR 20990.633655
BZD 2.170764
CAD 1.489966
CDF 3069.34438
CHF 0.938779
CLF 0.037214
CLP 1026.858308
CNY 7.688569
CNH 7.624414
COP 4635.243595
CRC 550.88022
CUC 1.070951
CUP 28.380193
CVE 110.121116
CZK 25.246052
DJF 191.779421
DKK 7.457243
DOP 64.85526
DZD 142.783439
EGP 52.840281
ERN 16.06426
ETB 133.339479
FJD 2.396999
FKP 0.819458
GBP 0.829521
GEL 2.912726
GGP 0.819458
GHS 17.661923
GIP 0.819458
GMD 76.575294
GNF 9283.869703
GTQ 8.325122
GYD 225.315603
HKD 8.327311
HNL 27.172496
HRK 7.377812
HTG 141.714836
HUF 406.943597
IDR 16765.572514
ILS 4.016408
IMP 0.819458
INR 90.370194
IQD 1410.756706
IRR 45078.992891
ISK 148.584172
JEP 0.819458
JMD 170.866746
JOD 0.759413
JPY 163.910068
KES 138.918489
KGS 92.313094
KHR 4373.285868
KMF 493.038894
KPW 963.855385
KRW 1497.369933
KWD 0.328429
KYD 0.897427
KZT 530.157297
LAK 23636.117069
LBP 96440.690673
LKR 315.078319
LRD 204.083345
LSL 18.846475
LTL 3.162239
LVL 0.647807
LYD 5.226171
MAD 10.635304
MDL 19.314763
MGA 4982.489883
MKD 61.534599
MMK 3478.406088
MNT 3639.090497
MOP 8.623233
MRU 42.90494
MUR 49.693988
MVR 16.546042
MWK 1867.459978
MXN 21.572963
MYR 4.693442
MZN 68.434735
NAD 18.846475
NGN 1786.431742
NIO 39.628222
NOK 11.784104
NPR 145.378049
NZD 1.796429
OMR 0.412122
PAB 1.076993
PEN 4.039622
PGK 4.323351
PHP 62.602405
PKR 299.056653
PLN 4.327603
PYG 8420.997132
QAR 3.927069
RON 4.957313
RSD 116.897474
RUB 104.994676
RWF 1476.271105
SAR 4.022479
SBD 8.932536
SCR 14.372721
SDG 644.176446
SEK 11.594075
SGD 1.422903
SHP 0.819458
SLE 24.471554
SLL 22457.297209
SOS 615.495794
SRD 37.450887
STD 22166.517181
SVC 9.423687
SYP 2690.796041
SZL 18.841382
THB 36.743242
TJS 11.447942
TMT 3.759037
TND 3.343731
TOP 2.508274
TRY 36.806443
TTD 7.318438
TWD 34.538611
TZS 2875.442949
UAH 44.460009
UGX 3941.849583
USD 1.070951
UYU 44.991215
UZS 13771.006814
VEF 3879575.160581
VES 47.815262
VND 27068.278859
VUV 127.14545
WST 2.99993
XAF 655.101046
XAG 0.031749
XAU 0.000394
XCD 2.894298
XDR 0.807445
XOF 655.101046
XPF 119.331742
YER 267.550279
ZAR 18.887238
ZMK 9639.840831
ZMW 29.319691
ZWL 344.845687
  • RBGPF

    61.4000

    61.4

    +100%

  • SCS

    0.0600

    13.14

    +0.46%

  • JRI

    0.1600

    13.53

    +1.18%

  • BCC

    1.4700

    142.32

    +1.03%

  • GSK

    -0.3700

    36.29

    -1.02%

  • NGG

    -0.3600

    63.94

    -0.56%

  • RIO

    -3.0400

    64.43

    -4.72%

  • CMSD

    0.2350

    25.125

    +0.94%

  • CMSC

    0.1600

    24.84

    +0.64%

  • AZN

    -0.2000

    64.49

    -0.31%

  • RELX

    0.3200

    47.98

    +0.67%

  • BTI

    -0.0100

    35.39

    -0.03%

  • BCE

    0.3000

    28.37

    +1.06%

  • VOD

    -0.0100

    9.31

    -0.11%

  • RYCEF

    0.0100

    7.15

    +0.14%

  • BP

    -0.8800

    28.93

    -3.04%

Mixed results for Moderna mRNA flu vaccine trial
Mixed results for Moderna mRNA flu vaccine trial / Photo: Maddie Meyer - GETTY IMAGES/AFP

Mixed results for Moderna mRNA flu vaccine trial

US biotech company Moderna said Thursday it had mixed results from a large-scale trial of its mRNA flu shot, based on the same technology used in its successful Covid-19 vaccine.

Text size:

Moderna's experimental mRNA-1010 flu shot is "quadrivalent," meaning it targets four strains of flu: A/H1N1, A/H3N2, B/Yamagata and B/Victoria -- selected based on recommendations by the World Health Organization (WHO).

The Massachusetts-based company said that its flu shot generated an immune response against influenza A strains that was equal or superior to that of already licensed vaccines.

However, it fell short of the already approved vaccines against strains of the less-common influenza B, Moderna said in a statement.

"Today's results represent an important step forward in the development of mRNA-based influenza vaccines," Moderna president Stephen Hoge said.

"We have already updated the vaccine that we believe could improve immune responses against influenza B and will seek to quickly confirm those improvements in an upcoming clinical study."

The Phase 3 trial of the mRNA shot involved 6,102 adults in Argentina, Australia, Colombia, Panama, and the Philippines during the Southern Hemisphere influenza season.

Participants received a single dose of mRNA-1010 or a single dose of a licensed influenza vaccine.

Moderna said 70 percent of the mRNA-1010 recipients reported adverse reactions such as headaches, swelling and fatigue compared to 48 percent in the other group.

Virus strains have to be selected six to nine months before the vaccines are intended to be used, and their efficacy is approximately 40 to 60 percent.

Moderna is simultaneously conducting an efficacy trial of its vaccine.

Moderna and other vaccine manufacturers, including Sanofi, hope that mRNA technology -- which provokes an immune response by delivering genetic molecules containing the code for key parts of a pathogen into human cells -- can accelerate immunization development and production, and heighten efficacy.

There are some three to five million severe influenza cases annually worldwide and between 290,000 and 650,000 deaths, the WHO says.

Moderna's stock price was down more than six percent in after-hours trading in New York.

(T.Burkhard--BBZ)